Cooper-Jones Brit, Mason Jeff, Kamel Chris, Mittmann Nicole, Dunfield Lesley
RinggoldID:6319Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada.
Healthc Manage Forum. 2022 May;35(3):127-129. doi: 10.1177/08404704211061954. Epub 2022 Mar 17.
The COVID-19 pandemic resulted in a rapid adoption of virtual care. Virtual care existed before the pandemic for specific conditions and circumstances. Health Technology Assessment (HTA) of virtual care evaluated clinical and cost-effectiveness to inform decisions about the optimal use prior to the pandemic but the necessary implementation of virtual care during the pandemic meant HTA was not feasible prior to adoption. The questions for HTA no longer focused on clinical or cost-effectiveness and focused on implementation considerations. Health technology assessment post-adoption of virtual care included questions such as the appropriate medical conditions for virtual care, training, billing, patient and clinician perspectives and experiences, and equity of access. Moving forward, it is important for HTA organizations to identify new and emerging virtual care technologies, explore early and other types of evidence, assess the potential impact on the healthcare system, and explore the operational considerations.
新冠疫情导致虚拟医疗迅速普及。在疫情之前,虚拟医疗就已存在于特定的病情和情形中。疫情之前,虚拟医疗的卫生技术评估(HTA)会评估临床和成本效益,为有关最佳使用方式的决策提供信息,但疫情期间虚拟医疗的必要实施意味着在采用之前进行HTA是不可行的。HTA的问题不再聚焦于临床或成本效益,而是聚焦于实施方面的考量。虚拟医疗采用后的卫生技术评估包括诸如虚拟医疗适用的医疗状况、培训、计费、患者和临床医生的观点与体验以及获取的公平性等问题。展望未来,HTA组织识别新出现的虚拟医疗技术、探索早期证据及其他类型的证据、评估对医疗系统的潜在影响并探讨运营方面的考量是很重要的。